Last reviewed · How we verify
NCT04383067
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
Phase 2 trial testing Tumor Infiltrating Lymphocytes (TIL) in Metastatic Urothelial Carcinoma in 20 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Sheba Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 12 May 2020 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Tumor Infiltrating Lymphocytes (TIL) — full drug profile →
- Proleukin (ALDESLEUKIN) — full drug profile →
Conditions studied
- Metastatic Urothelial Carcinoma — all drugs for Metastatic Urothelial Carcinoma →
Sponsor
Sheba Medical Center
Who can join
18 and older, any sex, with Metastatic Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
T cells in health and disease.
Sun L, Su Y, Jiao A, Wang X, et al · · 2023 · cited 717× · PMID 37332039 · DOI 10.1038/s41392-023-01471-y -
Metastatic Urothelial Cancer: a rapidly changing treatment landscape.
Stecca C, Abdeljalil O, Sridhar SS. · · 2021 · cited 40× · PMID 34616491 · DOI 10.1177/17588359211047352 -
A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.
Patel DM, Mateen R, Qaddour N, Carrillo A, et al · · 2024 · cited 13× · PMID 38254823 · DOI 10.3390/cancers16020335 -
Clinical Trials of Cellular Therapies in Solid Tumors.
Secondino S, Canino C, Alaimo D, Muzzana M, et al · · 2023 · cited 12× · PMID 37509328 · DOI 10.3390/cancers15143667 -
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E, Mollica V, Nuvola G, Marchetti A, et al · · 2022 · cited 8× · PMID 35720644 · DOI 10.2147/cmar.s287904
Verify or expand the search:
- PubMed search for NCT04383067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tumor Infiltrating Lymphocytes (TIL)
Trials testing the same drug.
- NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
- NCT06530303 — Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer · Phase 1, PHASE2 · recruiting
- NCT06532799 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer · Phase 1, PHASE2 · recruiting
- NCT06532812 — TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06538012 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer · Phase 1, PHASE2 · recruiting
Other recruiting trials for Metastatic Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting
- NCT06524544 — A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of · Phase 3 · recruiting
- NCT06862219 — A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer · Phase 4 · recruiting
Other Sheba Medical Center trials
Trials by the same sponsor.
- NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
- NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
- NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
- NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04383067 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
- Last refreshed: 11 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04383067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing